EUSA Pharma Clinical Research and Development seeks to extend and enhance the use of its products to maximise their clinical benefit to patients suffering from cancer or rare diseases with high unmet medical need. The devastating impact of these diseases drives our sense of urgency to develop solutions that have a meaningful impact on patients’ lives.

To extend and enhance the value of our products to patients with cancer or rare diseases, our Clinical Development and Operations group is focused on optimising their use in patients with multicentric Castleman disease or neuroblastoma, and on innovatively investigating their use in new indications.

Phase 2

Siltuximab dose escalation in patients with siltuximab-relapsed/refractory (R/R) idiopathic multicentric Castleman disease (iMCD)

Phase 2

Siltuximab in patients with interleukin-6 (IL-6)-associated histiocytic or lymphoproliferative disorders (LPDs) beyond iMCD

Phase 3

Siltuximab in patients with viral acute respiratory distress syndrome (ARDS) (‘SILVAR’)

Further Information
Phase 1b

Dinutuximab beta plus induction chemotherapy regimens in patients with newly diagnosed high-risk neuroblastoma (HRNB)

Further Information

If you are interested in participating in clinical trials worldwide, please contact ClinicalR&D@eusapharma.com